New vaccine targets tough ovarian cancer in tiny trial
NCT ID NCT07455071
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a personalized vaccine (YS247) made from a patient's own immune cells to fight a specific type of ovarian cancer (HRD-negative). Only 9 women who haven't been cured by standard therapy will take part. The main goal is to check safety, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized dendritic cell vaccine (YS247)
What this could lead to
If it works, this could point toward a new treatment option for a hard-to-treat form of ovarian cancer.
What could go wrong
This is a very early, small trial (9 people) focused on safety, not effectiveness. The vaccine is personalized and complex, so it may not work for everyone or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HRD-NEGATIVE EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••